Prognostic factors in Hodgkin lymphoma

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 6, Issue 1, 2014, Pages 1-10

  Cuccaro, Annarosa ^a   Bartolomei, Francesca ^a   Cupelli, Elisa ^a   Galli, Eugenio ^a   Giachelia, Manuela ^a   Hohaus, Stefan ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BLEOMYCIN; CD30 ANTIGEN; CHEMOKINE; CYCLOPHOSPHAMIDE; CYTOKINE; DACARBAZINE; DNA; DOXORUBICIN; INTERLEUKIN 10; INTERLEUKIN 6; MESSENGER RNA; PREDNISONE; PROCARBAZINE; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA; VINBLASTINE; VINCRISTINE; CELL DNA; MICRORNA; PROTEIN BCL 2; TUMOR MARKER; TUMOR NECROSIS FACTOR; VIRUS DNA;

AGE; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CYTOKINE PRODUCTION; ERYTHROCYTE SEDIMENTATION RATE; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; LEUKOCYTOSIS; LEUKOPENIA; LUNG TOXICITY; LYMPHOCYTOPENIA; MONOCYTOSIS; POSITRON EMISSION TOMOGRAPHY; RELIABILITY; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; CANCER SURVIVAL; EPSTEIN BARR VIRUS; FEVER; GENDER; GENETIC ASSOCIATION; NIGHT SWEAT; PROTEIN EXPRESSION; REED STERNBERG CELL; REVIEW; WEIGHT REDUCTION;

EID: 84904420760     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2014.053     Document Type: Article

References (69)

1. Casasnovas RO, Mounier N, Brice P, Divine M, Morschhauser F, Gabarre J, Blay JY, Voillat L, Lederlin P, Stamatoullas A, Bienvenu J, Guiguet M, Intrator L, Grandjean M, Brière J, Ferme C, Salles G; Groupe d'Etude des Lymphomes de l'Adulte. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007; 25:1732-40. http://dx.doi.org/10.1200/JCO.2006.08.1331 PMid:17389336
2. Carbone PP, Kaplan HS, Musshoff K, Smithers, DW and Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Research. 1971; 31:1860- 1861. PMid:5121694
3. Eichenauer DA, Engert A, Dreyling M; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011; 22 Suppl 6:55-8. http://dx.doi.org/10.1093/annonc/mdr378 PMid:21908505
4. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med. 1998; 339:1506-14. http://dx.doi.org/10.1056/NEJM199811193392104 PMid:9819449
5. Gobbi PG, Bassi E, Bergonzi M, Merli F, Coriani C, Iannitto E, Luminari S, Polimeno G, Federico M. Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. Hematol Oncol. 2012; 30:194-9. http://dx.doi.org/10.1002/hon.1024 PMid:22271092
6. Berkowitz A, Basu S, Srinivas S, Sankaran S, Schuster S, Alavi A. Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. Nucl Med Commun. 2008; 29:521-6. http://dx.doi.org/10.1097/MNM.0b013e3282f813a4 PMid:18458598
7. Gobbi PG. Tumor burden in Hodgkin's lymphoma: Much more than the best prognostic factor. Critical Reviews in Oncology/Hematology 2014; 90:17-23. http://dx.doi.org/10.1016/j.critrevonc.2013.11.002 PMid:24290380
8. Gobbi PG, Bergonzi M, Bassi E, Merli F, Coriani C, Stelitano C, Iannitto E, Federico M. Tumor burden in Hodgkin'slymphoma can be reliably estimated from a few staging parameters. Oncol Rep 2012; 28:815-20. PMid:22752083
9. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998; 339:1506-14. http://dx.doi.org/10.1056/NEJM199811193392104 PMid:9819449
10. Massini G, Siemer D, Hohaus S. EBV in Hodgkin lymphoma. Mediterr J Hematol Infect Dis. 2009; 1:e2009013. PMid:21416003 PMCid:PMC3033177
11. Jarrett RF, Stark GL, White J, Angus B, Alexander FE, Krajewski AS, Freeland J, Taylor GM, Taylor PR; Scotland and Newcastle Epidemiology of Hodgkin Disease Study Group. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood. 2005;106:2444-51. http://dx.doi.org/10.1182/blood-2004-09-3759 PMid:15941916
12. Keegan TH, Glaser SL, Clarke CA, Gulley ML, Craig FE, Digiuseppe JA, Dorfman RF, Mann RB, Ambinder RF. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol. 2005; 23:7604-13. http://dx.doi.org/10.1200/JCO.2005.02.6310 PMid:16186595
13. Diepstra A, van Imhoff GW, Schaapveld M, Karim-Kos H, van den Berg A, Vellenga E, Poppema S. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol. 2009; 27:3815-21. http://dx.doi.org/10.1200/JCO.2008.20.5138 PMid:19470931
14. Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, Parsons B, Smith S, Larsen A, McKoy JM, Jovanovic B, Gregory S, Gordon LI, Smith SM. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119:692-5. http://dx.doi.org/10.1182/blood-2011-09-378414 PMid:22117038
15. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program. 2003:225-47. http://dx.doi.org/10.1182/asheducation-2003.1.225
16. Wongso D, Fuchs M, Plutschow A, Klimm B, Sasse S, Hertenstein B, Maschmeyer B, Vieler T, Duhrsen U, Lindemann W, Aulitzky W, Diehl V, Borchmann P, and Engert A. Treatment-Related Mortality in Patients With Advanced-Stage Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group. J Clin Oncol. 2013; 31:2819-24. http://dx.doi.org/10.1200/JCO.2012.47.9774 PMid:23796987
17. Klimm B, Reineke T, Haverkamp H, Behringer K, Eich HT, Josting A, Pfistner B, Diehl V, Engert A; German Hodgkin Study Group. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. J Clin Oncol. 2005; 23:8003-11. http://dx.doi.org/10.1200/JCO.2005.205.60 PMid:16204002
18. Hohaus S, Massini G, Giachelia M, Vannata B, Bozzoli V, Cuccaro A, D'Alo' F, Larocca LM, Raymakers RA, Swinkels DW, Voso MT, Leone G. Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol. 2010; 28:2538-43. http://dx.doi.org/10.1200/JCO.2009.27.6873 PMid:20406921
19. Hohaus S, Giachelia M, Cuccaro A, Voso MT, Leone G. Iron in Hodgkin's lymphoma. Crit Rev Oncog. 2013; 18:463-9. http://dx.doi.org/10.1615/CritRevOncog.2013007765
20. Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica. 2012; 97:262-9. http://dx.doi.org/10.3324/haematol.2011.050138 PMid:21993683 PMCid:PMC3269488
21. Dimopoulos MA, Cabanillas F, Lee JJ, Swan F, Fuller L, Allen PK, Hagemeister FB. Prognostic role of serum beta 2-microglobulin in Hodgkin's disease. J Clin Oncol. 1993; 11:1108-11. PMid:8501496
22. Chronowski GM, Wilder RB, Tucker SL, Ha CS, Sarris AH, Hagemeister FB, Barista I, Hess MA, Cabanillas F, Cox JD. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer. 2002; 95:2534-8. http://dx.doi.org/10.1002/cncr.10998 PMid:12467067
23. Vassilakopoulos TP, Nadali G, Angelopoulou MK, Siakantaris MP, Dimopoulou MN, Kontopidou FN, Karkantaris C, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Pizzolo G, Pangalis GA. The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma. Haematologica. 2002; 87:701-8. PMid:12091120
24. Sarris AH1, Kliche KO, Pethambaram P, Preti A, Tucker S, Jackow C, Messina O, Pugh W, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera J, Fritsche H, Witzig T, Duvic M, Andreeff M, Cabanillas F. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 1999; 10:433-40. http://dx.doi.org/10.1023/A:1008301602785
25. Bohlen H, Kessler M, Sextro M, Diehl V, Tesch H. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol. 2000; 79:110-113. http://dx.doi.org/10.1007/s002770050564 PMid:10803931
26. Axdorph U, Sjöberg J, Grimfors G, Landgren O, Porwit-MacDonald A, Björkholm M. Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease. Ann Oncol. 2000; 11:1405-1411. http://dx.doi.org/10.1023/A:1026551727795 PMid:11142480
27. Viviani S, Notti P, Bonfante V, Verderio P, Valagussa P, Bonadonna G. Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experience. Med Oncol. 2000; 17:59-63. http://dx.doi.org/10.1007/BF02826218 PMid:10713662
28. Vassilakopoulos TP, Nadali G, Angelopoulou MK, Siakantaris MP, Dimopoulou MN, Kontopidou FN, Rassidakis GZ, Doussis-Anagnostopoulou IA, Hatzioannou M, Vaiopoulos G, Kittas C, Sarris AH, Pizzolo G, Pangalis GA. Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica. 2001;86:274-281. PMid:11255274
29. Herling M1, Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, Kliche KO, Nadali G, Viviani S, Bonfante V, Giardini R, Chilosi M, Kittas C, Gianni AM, Bonadonna G, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH. Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clin Cancer Res. 2003; 9:2114-2120. PMid:12796376
30. Hohaus S, Giachelia M, Massini G, Vannata B, Criscuolo M, Martini M, D'Alo' F, Voso MT, Larocca LM, Leone G. Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. Leuk Res. 2009;33:1352-6. http://dx.doi.org/10.1016/j.leukres.2009.01.009 PMid:19201467
31. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res. 1993;53:2118-22. PMid:8481913
32. Nadali G, Tavecchia L, Zanolin E, Bonfante V, Viviani S, Camerini E, Musto P, Di Renzo N, Carotenuto M, Chilosi M, Krampera M, Pizzolo G. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood. 1998; 91:3011-6. PMid:9531614
33. Ma Y, Visser L, Roelofsen H, de Vries M, Diepstra A, van Imhoff G, van der Wal T, Luinge M, Alvarez-Llamas G, Vos H, Poppema S, Vonk R, van den Berg A. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood. 2008; 111:2339-46. http://dx.doi.org/10.1182/blood-2007-09-112128 PMid:18070985
34. Plattel WJ, van den Berg A, Visser L, van der Graaf AM, Pruim J, Vos H, Hepkema B, Diepstra A, van Imhoff GW. Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma. Haematologica. 2012; 97:410-5. http://dx.doi.org/10.3324/haematol.2011.053199 PMid:22058214 PMCid:PMC3291596
35. Jones K, Vari F, Keane C, Crooks P, Nourse JP, Seymour LA, Gottlieb D, Ritchie D, Gill D, Gandhi MK. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res. 2013;19:731-42. http://dx.doi.org/10.1158/1078-0432.CCR-12-2693 PMid:23224400
36. Bennett MH, MacLennan KA, Easterling MJ, Vaughan Hudson B, Jelliffe AM, Vaughan Hudson G. The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease: an analysis of 271 non-laparotomised cases (BNLI report no. 22). Clin Radiol. 1983;34:497-501. http://dx.doi.org/10.1016/S0009-9260(83)80148-2
37. Van Spronsen DJ, Vrints LW, Hofstra G, Crommelin MA, Coebergh JW, Breed WP. Disappearance of prognostic significance of histopathological grading of nodular sclerosing Hodgkin's disease for unselected patients, 1972-92. Br J Haematol. 1997;96:322-7. http://dx.doi.org/10.1046/j.1365-2141.1997.d01-2010.x PMid:9029020
38. Ferry JA, Linggood RM, Convery KM, Efird JT, Eliseo R, Harris NL. Hodgkin disease, nodular sclerosis type. Implications of histologic subclassification. Cancer. 1993;71:457-63. http://dx.doi.org/10.1002/1097-0142(19930115)71:2<457::AID-CNCR2820710229>3.0.CO;2-U
39. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, Viviani S, Bonfante V, Nadali G, Herling M, Angelopoulou MK, Giardini R, Chilosi M, Kittas C, McDonnell TJ, Bonadonna G, Gianni AM, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood. 2002; 100:3935-3941. http://dx.doi.org/10.1182/blood.V100.12.3935 PMid:12433696
40. Sup SJ, Alema-y CA, Pohlman B, Elson P, Malhi S, Thakkar S, Steinle R, Hsi ED. Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol. 2005; 23:3773-3779. http://dx.doi.org/10.1200/JCO.2005.04.358 PMid:15809450
41. Smolewski P, Robak T, Krykowski E, Blasi-ska-Morawiec M, Niewiadomska H, Pluzanska A, Chmielowska E, Zambrano O Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res. 2000; 6:1150-1160. PMid:10741746
42. Montalbán C, García JF, Abraira V, González-Camacho L, Morente MM, Bello JL, Conde E, Cruz MA, García-Sanz R, García-Lara-a J, Grande C, Llanos M, Martínez R, Flores E, Méndez M, Ponderós C, Rayón C, Sánchez-Godoy P, Zamora J, Piris MA; Spanish Hodgkin's Lymphoma Study Group. Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol. 2004; 22:1664-1673. http://dx.doi.org/10.1200/JCO.2004.06.105 PMid:15117989
43. Alvaro T, Lejeune M, Salvadó MT, Bosch R, García JF, Jaén J, Banham AH, Roncador G, Montalbán C, Piris MA. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005; 11:1467-1473. http://dx.doi.org/10.1158/1078-0432.CCR-04-1869 PMid:15746048
44. Kelley TW, Pohlman B, Elson P, and Hsi ED. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol. 2007; 128:958-65. http://dx.doi.org/10.1309/NB3947K383DJ0LQ2 PMid:18024321
45. Sánchez-Aguilera A, Montalbán C, de la Cueva P, Sánchez-Verde L, Morente MM, García-Cosío M, García-Lara-a J, Bellas C, Provencio M, Romagosa V, de Sevilla AF, Menárguez J, Sabín P, Mestre MJ, Méndez M, Fresno MF, Nicolás C, Piris MA, García JF; Spanish Hodgkin Lymphoma Study Group. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood. 2006;108:662-8. http://dx.doi.org/10.1182/blood-2005-12-5125 PMid:16551964
46. Von Wasielewski R, Seth S, Franklin J, Fischer R, Hübner K, Hansmann ML, Diehl V, Georgii A. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood. 2000;95:1207-13. PMid:10666192
47. Chetaille B, Bertucci F, Finetti P, Esterni B, Stamatoullas A, Picquenot JM, Copin MC, Morschhauser F, Casasnovas O, Petrella T, Molina T, Vekhoff A, Feugier P, Bouabdallah R, Birnbaum D, Olive D, Xerri L. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood. 2009; 113:2765-75. http://dx.doi.org/10.1182/blood-2008-07-168096 PMid:19096012
48. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010; 362:875-85. http://dx.doi.org/10.1056/NEJMoa0905680 PMid:20220182 PMCid:PMC2897174
49. Steidl C, Farinha P, Gascoyne RD. Macrophages predict treatment outcome in Hodgkin's lymphoma. Haematologica. 2011;96:186-9. http://dx.doi.org/10.3324/haematol.2010.033316 PMid:21282720 PMCid:PMC3031684
50. Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, Bozzoli V, Criscuolo M, D'Alò F, Martini M, Larocca LM, Voso MT, Leone G. Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Ann Oncol. 2009;20:1408-13. http://dx.doi.org/10.1093/annonc/mdp006 PMid:19465421
51. Hohaus S, Santangelo R, Giachelia M, Vannata B, Massini G, Cuccaro A, Martini M, Cesarini V, Cenci T, D'Alo F, Voso MT, Fadda G, Leone G, Larocca LM. The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. Clin Cancer Res. 2011; 17:2885-92. http://dx.doi.org/10.1158/1078-0432.CCR-10-3327 PMid:21478335
52. Reichel JB, Eng K, Elemento O, Cesarman E, Roshal M. Exome Sequencing Of Purified Hodgkin Reed-Sternberg Cells Reveals Recurrent Somatic Mutations In Genes Responsible For Antigen Presentation, Chromosome Integrity, Transcriptional Regulation and Protein Ubiquitination. Blood 2013 (ASH Annual Meeting Abstracts), 122, 625.
53. Gunawardana J, Chan FC, Telenius A, Woolcock B, Kridel R, Tan KL, Ben-Neriah S, Mottok A, Lim RS, Boyle M, Rogic S, Rimsza LM, Guiter C, Leroy K, Gaulard P, Haioun C, Marra MA, Savage KJ, Connors JM, Shah SP, Gascoyne RD, Steidl C. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet. 2014; 46:329-35. http://dx.doi.org/10.1038/ng.2900 PMid:24531327
54. Gandhi MK, Lambley E, Burrows J, Dua U, Elliott S, Shaw PJ, Prince HM, Wolf M, Clarke K, Underhill C, Mills T, Mollee P, Gill D, Marlton P, Seymour JF, Khanna R. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res. 2006; 12:460-4. http://dx.doi.org/10.1158/1078-0432.CCR-05-2008 PMid:16428487
55. Kanakry JA, Li H, Gellert LL, Lemas MV, Hsieh WS, Hong F, Tan KL, Gascoyne RD, Gordon LI, Fisher RI, Bartlett NL, Stiff P, Cheson BD, Advani R, Miller TP, Kahl BS, Horning SJ, Ambinder RF. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood. 2013; 121:3547-53. http://dx.doi.org/10.1182/blood-2012-09-454694 PMid:23386127 PMCid:PMC3643756
56. Enciso-Mora V, Broderick P, Ma Y, Jarrett RF, Hjalgrim H, Hemminki K, van den Berg A, Olver B, Lloyd A, Dobbins SE, Lightfoot T, van Leeuwen FE, Försti A, Diepstra A, Broeks A, Vijayakrishnan J, Shield L, Lake A, Montgomery D, Roman E, Engert A, von Strandmann EP, Reiners KS, Nolte IM, Smedby KE, Adami HO, Russell NS, Glimelius B, Hamilton-Dutoit S, de Bruin M, Ryder LP, Molin D, Sorensen KM, Chang ET, Taylor M, Cooke R, Hofstra R, Westers H, van Wezel T, van Eijk R, Ashworth A, Rostgaard K, Melbye M, Swerdlow AJ, Houlston RS. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat Genet. 2010;42:1126-30. http://dx.doi.org/10.1038/ng.696 PMid:21037568
57. Cozen W, Li D, Best T, Van Den Berg DJ, Gourraud PA, Cortessis VK, Skol AD, Mack TM, Glaser SL, Weiss LM, Nathwani BN, Bhatia S, Schumacher FR, Edlund CK, Hwang AE, Slager SL, Fredericksen ZS, Strong LC, Habermann TM, Link BK, Cerhan JR, Robison LL, Conti DV, Onel K. A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. Blood. 2012; 119:469-75. http://dx.doi.org/10.1182/blood-2011-03-343921 PMid:22086417 PMCid:PMC3257012
58. Urayama KY, Jarrett RF, Hjalgrim H, Diepstra A, Kamatani Y, Chabrier A, Gaborieau V, Boland A, Nieters A, Becker N, Foretova L, Benavente Y, Maynadié M, Staines A, Shield L, Lake A, Montgomery D, Taylor M, Smedby KE, Amini RM, Adami HO, Glimelius B, Feenstra B, Nolte IM, Visser L, van Imhoff GW, Lightfoot T, Cocco P, Kiemeney L, Vermeulen SH, Holcatova I, Vatten L, Macfarlane GJ, Thomson P, Conway DI, Benhamou S, Agudo A, Healy CM, Overvad K, Tjønneland A, Melin B, Canzian F, Khaw KT, Travis RC, Peeters PH, González CA, Quirós JR, Sánchez MJ, Huerta JM, Ardanaz E, Dorronsoro M, Clavel-Chapelon F, Bueno-de-Mesquita HB, Riboli E, Roman E, Boffetta P, de Sanjosé S, Zelenika D, Melbye M, van den Berg A, Lathrop M, Brennan P, McKay JD. Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J Natl Cancer Inst. 2012; 104:240-53. http://dx.doi.org/10.1093/jnci/djr516 PMid:22286212 PMCid:PMC3274508
59. Hohaus S, Massini G, D'Alo' F, Guidi F, Putzulu R, Scardocci A, Rabi A, Di Febo AL, Voso MT, Leone G. Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis. Clin Cancer Res. 2003; 9:3435-40. PMid:12960134
60. Hohaus S, Di Ruscio A, Di Febo A, Massini G, D'Alo' F, Guidi F, Mansueto G, Voso MT, Leone G. Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res. 2005; 11:2175-9. http://dx.doi.org/10.1158/1078-0432.CCR-04-1250 PMid:15788664
61. Ribrag V, Koscielny S, Casasnovas O, Cazeneuve C, Brice P, Morschhauser F, Gabarre J, Stamatoullas A, Lenoir G, Salles G; Groupe d'Etude des Lymphomes agressifs group, Laboratoire de Génétique et de recherche translationnelle, and Institut Gustave Roussy. Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood. 2009; 113:3307-13. http://dx.doi.org/10.1182/blood-2008-03-148874 PMid:18768784
62. Lourenço GJ, Lorand-Metze I, Delamain MT, Miranda EC, Kameo R, Metze K, Lima CS. Polymorphisms of glutathione S-transferase mu 1, theta 1, and pi 1 genes and prognosis in Hodgkin lymphoma. Leuk Lymphoma. 2010; 51:2215-21. http://dx.doi.org/10.3109/10428194.2010.527402 PMid:20977336
63. Morabito F, Hohaus S, Mammi C, Marcheselli L, Gentile M, Merli F, Montanini A, Stelitano C, La Sala A, Scalone R, Voso MT, Luminari S, Iannitto E, Gobbi P, Federico M. Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leuk Lymphoma. 2012;53:406-10. http://dx.doi.org/10.3109/10428194.2011.623254 PMid:21916526
64. Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H. Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma. Leuk Lymphoma. 2012; 53:1934-44. http://dx.doi.org/10.3109/10428194.2012.682307 PMid:22475179
65. Schoof N, Franklin J, Fürst R, Zander T, von Bonin F, Peyrade F, Trümper L, Diehl V, Engert A, Kube D, Re D. Interleukin-10 gene polymorphisms are associated with freedom from treatment failure for patients with Hodgkin lymphoma. Oncologist. 2013;18:80-9. http://dx.doi.org/10.1634/theoncologist.2012-0291 PMid:23299779 PMCid:PMC3556261
66. Ghesquières H, Maurer MJ, Casasnovas O, Ansell SM, Larrabee BR, Lech-Maranda E, Novak AJ, Borrel AL, Slager SL, Brice P, Allmer C, Brion A, Ziesmer SC, Morschhauser F, Habermann TM, Gaillard I, Link BK, Stamatoullas A, Fermé C, Dogan A, Macon WR, Audouin J, Cerhan JR, Salles G. Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts. Cytokine. 2013; 64:523-31. http://dx.doi.org/10.1016/j.cyto.2013.08.002 PMid:24008079
67. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, Rudolph C, Diehl V, Engert A. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol. 2002; 20:221-30. http://dx.doi.org/10.1200/JCO.20.1.221 PMid:11773173
68. Hohaus S, Giachelia M, Di Febo A, Martini M, Massini G, Vannata B, D'Alo' F, Guidi F, Greco M, Pierconti F, Larocca LM, Voso MT, Leone G. Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol. 2007;18:1376-81. http://dx.doi.org/10.1093/annonc/mdm132 PMid:17496310
69. Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, Louie D, Gonzales M, Walits J, Coady-Lyons N, Qin J, Frank R, Bertino JR, Goy A, Noy A, O'Brien JP, Straus D, Portlock CS, Yahalom J. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001; 97:616-23. http://dx.doi.org/10.1182/blood.V97.3.616 PMid:11157476